Immunological monitoring for prediction of clinical response to antitumor vaccine therapy

Immunotherapy has shown promising results in a variety of cancers, including melanoma. However, the responses to therapy are usually heterogeneous, and understanding the factors affecting clinical outcome is still not achieved. Here, we show that immunological monitoring of the vaccine therapy for melanoma patients may help to predict the clinical course of the disease. We studied cytokine profile of cellular Th1 (IL-2, IL-12, IFN-γ) and humoral Th2 (IL-4, IL-10) immune response, vascular endothelial growth factor (VEGFA), transforming growth factor-β 2 (TGF-β 2), S100 protein (S100A1B and S100BB), adhesion molecule CD44 and serum cytokines β2-microglobulin to analyze different peripheral blood mononuclear cell subpopuations of patients treated with dendritic vaccines and/or cyclophosphamide in melanoma patients in the course of adjuvant treatment. The obtained data indicate predominance of cellular immunity in the first adjuvant group of patients with durable time to progression and shift to humoral with low cellular immunity in patients with short-term period to progression (increased levels of IL-4 and IL- 10). Beta-2 microglobulin was differentially expressed in adjuvant subgroups: its higher levels correlated with shorter progression-free survival and the total follow-up time. Immunoregulatory index was overall higher in patients with disease progression compared to the group of patients with no signs of disease progression. Copyright: Mikhaylova et al.

Mikhaylova I.N.1 , Shubina I.Zh.1 , Chkadua G.Z.1 , Petenko N.N.1 , Morozova L.F.1 , Burova O.S.1 , Beabelashvili R.Sh.2 , Parsunkova K.A.3 , Balatskaya N.V.4 , Chebanov D.K. 5 , Pospelov V.I.6 , Nazarova V.V. 1 , Vihrova A.S.1 , Cheremushkin E.A.1 , Molodyk A.A.1 , Kiselevsky M.V.1 , Demidov L.V.1
Impact Journals LLC
Номер выпуска
  • 1 N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
  • 2 Laboratory of Genetic Engineering, Institute of Experimental Cardiology, Russian Cardiological Research and Production Complex, Moscow, Russian Federation
  • 3 Diagnostic Laboratory Clinical Center “Optimum”, Sochi, Russian Federation
  • 4 Department of Immunology and Virology, Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russian Federation
  • 5 RUDN University, Moscow, Russian Federation
  • 6 “Genetic Technologies and Analyses”, Moscow, Russian Federation
Ключевые слова
B2-microglobulin; Cancer vaccine therapy; Melanoma; Predictive markers
Дата создания
Дата изменения
Постоянная ссылка

Другие записи

Skalny A.V., Skalnaya M.G., Klimenko L.L., Mazilina A.N., Tinkov A.A.
Molecular and Integrative Toxicology. Springer Science+Business Media B.V.. 2018. С. 211-230